CPR Invest - Defensive - I EUR - Acc ISIN : LU1203018707

CPR Invest - Defensive - I EUR - Acc
I(C) - LU1203018707
Asset class: Balanced

YTD
As of 17/11/2026
-3.34%

Risk IndicatorThe level of risk of the fund mainly reflects the risk of the market in which the fund is invested and, as the case may be, the leveraging strategy or inverse performance of the index. The capital initially invested does not benefit from any guarantee. The current level of risk does not indicate the future level of risk and may change over time. The lowest risk level is not equal to a risk-free investment.
1234567
Lower Risk
Higher Risk
The risk indicator assumes you keep the product according to the holding period.

NAV
As of 18/11/2026
€105,602.50

SFDR ClassificationSustainable Finance Disclosure Regulation
Art. 8

Fund AUM
As of 18/11/2026
€18.14M
A global balanced fund whose objective is to outperform the benchmark over a 2-year min. investment horizon while delivering a maximum ex-ante volatility of 7%. The fund's equity exposure ranges from 0% to 30%. Exposure to risk carrying assets, as defined in the fund's prospectus, is limited to 40% maximum. The modified duration on the fixed income section ranges between -2 and +8. CPR INVEST - Defensive is a feeder fund of French-domiciled FCP, CPR Croissance Defensive.

NAVs

NAV from 21/11/2016 to 18/11/2026
Select period
Created with Highcharts 11.4.8CPR Invest - Defensive - I EUR - AccJul '17Jul '18Jul '19Jul '20Jul '21Jul '22Jul '23Jul '24Jul '25Jul '2685K90K95K100K105K110K115K

Performance

Change in NAV in base 100
FundCPR Invest - Defensive - I EUR - Acc (7.12% over the period)
Select period
Created with Highcharts 11.4.8BCPR Invest - Defensive - I EUR - AccBenchmarkJul '17Jul '18Jul '19Jul '20Jul '21Jul '22Jul '23Jul '24Jul '25Jul '268090100110120130140
B. Since the beginning of this period, the reference indicator of the Sub-Fund is the capitalized €STR.Performance published and achieved before the date of the change corresponds to a different strategy from the current one.
* Rolling performance : for funds that have been launched since less than 1 year or 3 years or 5 years, the performance showed in the table in the 1 year or 3 years or 5 years column is the performance since inception of the fund.

All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.

Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.

The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).

The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
FundCPR Invest - Defensive - I EUR - Acc (7.12% over the period)
Select period
Created with Highcharts 11.4.8BCPR Invest - Defensive - I EUR - AccBenchmarkJul '17Jul '18Jul '19Jul '20Jul '21Jul '22Jul '23Jul '24Jul '25Jul '268090100110120130140
B. Since the beginning of this period, the reference indicator of the Sub-Fund is the capitalized €STR.Performance published and achieved before the date of the change corresponds to a different strategy from the current one.
* Rolling performance : for funds that have been launched since less than 1 year or 3 years or 5 years, the performance showed in the table in the 1 year or 3 years or 5 years column is the performance since inception of the fund.

All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.

Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.

The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).

The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.

Portfolio Analysis

Repartition 10/31/2026
Sector
Weight
ARI - EUROPEAN CREDIT- I2 - CInvestment Grade EMU14.39%
CPR INVEST - CLIMATE BONDS EURO - Z EURInvestment Grade EMU13.27%
BFT AUREUS ISR - Z (C)Money Market Investments10.72%
CPR ABSOLUTE RETURN BONDS - Z (C)Absolute Return Fixed Income10.09%
abrdn Em Mkt Lcl Ccy Dbt K Acc EURGovies Emerging Global9.84%
Amundi EUR Corporate Bond ESG ETF DR CInvestment Grade EMU9.51%
Amundi EUR Corporate Bond 1-5Y ESG ETF AInvestment Grade EMU7.43%
CPR INV B&W EU STRAT AUTO 2028 IIInvestment Grade Europe5.24%
Amundi MSCI World Swap II ETF AccEquities World5.04%
AMUN EUR HY Corp Bd ESG UCITS Dist (PAR)High Yield Europe2.32%

Management commentary

Effective date: 31/10/2026
The month of October 2026 was marked by a new surge in energy prices. Indeed, attacks on ships continued in the Strait of Hormuz, the Houthis claimed responsibility for strikes on several Saudi refineries, and Donald Trump hinted that US strikes on Iran could resume after the midterm elections on November 3. As a result, the price of Brent crude rose by nearly 14% over the month, reaching $118, its highest level in six months. The price of natural gas also increased sharply, reaching its highest level since the end of 2022. Another key event of the month was the sharp decline in technology stocks at the very end of the month, following disappointing earnings reports from Alphabet, Amazon, and Intel, which reignited doubts about the profitability of massive investments in AI.
 
The inflation indices published in October, covering the month of September, accelerated again due to energy prices. In the eurozone, headline inflation reached 3.8% compared to 3.2% in August, its highest level since September 2023, with the energy component rising by 18.8% year-on-year. In contrast, core inflation remained broadly stable at 2.5%. In the United States, headline inflation (CPI) rose from 3.4% to 3.7%, while core inflation climbed to 2.6%, slightly higher than expected. The September “core PCE” inflation came in at 3.1%.
 
Activity indicators continued to be solid. In the United States, Q3 GDP growth came in at 3.4% quarter-on-quarter annualized, above expectations, driven by consumption and business investment. However, after a strong report in August, the September employment report disappointed, with only 29,000 non-farm jobs created and an increase in the unemployment rate to 4.2%. In the eurozone, GDP grew by 0.4% in Q3, despite a surprise contraction of 0.1% in France, but the composite PMI fell to 51.9 in October from 53.1 in September, well below expectations. In China, GDP growth came in at 4.5% year-on-year in Q3, but the economy remains highly unbalanced and household consumption very weak.
 
After September, the first month in history during which the ECB, the Fed, and the BoJ all raised their key rates, these three central banks all decided to leave their rates unchanged in October. The Fed maintained the fed funds target range at 3.75/4%, but two FOMC members (Lisa Cook and Beth Hammack) voted in favor of another hike. Kevin Warsh indicated that the September rate hike had begun to take effect and that the tightening of financial conditions was paving the way for a more sustainable period of growth and price stability. For its part, the BoJ left its main policy rate at 1.25% but opened the door to a hike in December. Finally, the ECB left its deposit rate at 2.50%, even though energy prices in Europe are now between the “adverse” and “severe” scenarios mentioned in September, fueling upside risks for inflation and downside risks for growth. The Council debated a new rate hike but judged that uncertainties were still too high, while indicating that “the direction is quite clear” for all its members. For now, it does not see a substantial risk of second-round effects.
 
Despite the rise in oil prices, bond yields fell sharply over the month, benefiting from a flight to safe-haven assets at the end of the month and the central banks’ pause. The US 10-year yield fell by nearly 40 bps to 4.90%, after briefly exceeding 5.30% during the month. The German 10-year yield fell by about 25 bps over the month to 3.29%, returning to its end-August levels. In Japan, the 10-year yield fell back below the 3% mark, to 2.77%, its lowest level in nearly three months. Finally, gold fell again, by about 6% over the month, to just over $3,875 an ounce, penalized by the prospect of further Fed rate hikes.
 
Equity markets were shaken at the end of the month by doubts about the profitability of AI-related investments. The S&P 500 fell by 0.9% over the month and the Nasdaq by more than 5%, while the Dow Jones rose by 1.7%. The Eurostoxx 600 was more resilient, rising by 1.9%. Asian markets, more exposed to the semiconductor sector, fell sharply: the Nikkei lost nearly 5.2% and the MSCI Emerging dropped 8.1%, its worst month since the start of the war in Iran.

Within the Growth range, allocations favored broad indices and the US health care and energy sectors. Positions on the Nasdaq 100 and several thematic technology and emerging exposures were reduced.

CPR Croissance Défensive. The P share fell by 1.01%, compared to a 0.20% increase in the capitalized €STR. Euro investment grade credit was the main support in the face of the decline in technology and emerging exposures. Net equity exposure increased by 2.72 points to 22.00%, with a strengthening of North American equities (health care and energy sectors) and a reduction in emerging equities. Rate sensitivity rose from 2.62 to 2.95 points.

We approach November with a slightly cautious equity bias, an underweight in the US focused on technology, and a slight preference for health care and energy. On rates, we favor contained sensitivity and maturities of five to seven years. US high yield remains a selective source of carry, while quality euro credit remains preferred.

Characteristics

General data

Inception date
27/03/2015
First Nav Date
26/01/2011
Currency
EUR
Show more
Valuation
Daily
Minimum initial investment
100000 euros
Minimum additional investment
1 10/1000° share(s)/equity

Costs Composition

One-off costs upon entry or exit (Investment EUR 10,000)If you exit after 1 year
Entry costsThis includes distribution costs of 5.00% of amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge.Up to €500.00
Exit costsWe do not charge an exit fee for this product, but the person selling you the product may do so.€0.00
Ongoing costs taken each year (Investment EUR 10,000)
Management fees and other administrative or operating costs1.14% of the value of your investment per year. This percentage is based on actual costs over the last year.€108.02
Transaction costs0.00% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.€0.10
Incidental costs taken under specific conditions (Investment EUR 10,000)
Performance fees

20.00% annual outperformance of the reference asset 100% ESTR CAPITALISE (OIS) + 1.5%. The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee.The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.

The performance fee is paid even if the performance of the share over the performance observation period is negative, while remaining higher than the performance of the Reference Asset.

€0.00

Codification

ISIN code
LU1203018707
Bloomberg code
CPRDEIA LX
Reuters code
LP68308267

Investment Objective

A global balanced fund whose objective is to outperform the benchmark over a 2-year min. investment horizon while delivering a maximum ex-ante volatility of 7%. The fund's equity exposure ranges from 0% to 30%. Exposure to risk carrying assets, as defined in the fund's prospectus, is limited to 40% maximum. The modified duration on the fixed income section ranges between -2 and +8. CPR INVEST - Defensive is a feeder fund of French-domiciled FCP, CPR Croissance Defensive.

Documents

LanguageDocumentsTypeClosing Date
CS
PDF
14/09/2026
PDF
01/10/2026
EN
PDF
31/07/2025
PDF
31/01/2026
CS
PDF
31/10/2026
EN
PDF
26/10/2016
Prices expressed in a currency other than the base currency of the portfolio are available for information purposes only.
Nothing contained in this site constitutes a solicitation or offer by any member of the Amundi to provide any investment advice or service or to purchase or sell any financial instruments. The information it contains aims to inform the subscriber by providing information on the UCITS supplemental to that appearing in the Information Memorandum. The material provided on this site is presented as of the date shown and "as is". Amundi does not expressly or impliedly warrant the accuracy of the information provided on this site and expressly disclaims any warranties of fitness of this site for any particular purpose. This material reflects the opinion of the management company at the date of printing. The material is based upon information that we consider reliable, but we do not represent it is accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any subscription should be based solely on the Information Memorandum provided to subscribers prior to the subscription and/or available upon request.